Stefan Verlohren

Stefan Verlohren

Auto-generated profile, based on publicly available information

Stefan Verlohren

Department of Obstetrics and Fetal Medicine University Medical Center Hamburg‐Eppendorf Hamburg Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HZHarald Zeisler
Harald Zeisler
Elisa LlurbaElisa Llurba
Elisa Llurba
FCFrederic Chantraine
Frederic Chantraine
MVManu Vatish
Manu Vatish
ASAnne Cathrine Staff
Anne Cathrine Staff
SVStefan Verlohren
Stefan Verlohren
The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia, but its predictive value in women with suspected preeclampsia is unclear.

21 February 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
SRSarosh Rana
Sarosh Rana
CPCamille E. Powe
Camille E. Powe
SSSaira Salahuddin
Saira Salahuddin
SVStefan Verlohren
Stefan Verlohren
FPFrank H. Perschel
Frank H. Perschel
SKS. Ananth Karumanchi
S. Ananth Karumanchi
Background—: An imbalance in circulating angiogenic factors plays a central role in the pathogenesis of preeclampsia. Methods and Results—: We prospectively studied 616 women who were evaluated for suspected preeclampsia. We measured plasma levels of antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt1) and proangiogenic placental growth factor (PlGF) at presentation and examined for an association between the sFlt1/PlGF ratio and subsequent adverse maternal and perinatal outcomes within 2 weeks. The median sFlt1/PlGF ratio at presentation was elevated in participants who experienced any adverse outcome compared with those who did not (47.0 [25th–75th percentile, 15.5–112.2] versus 10.8 [25th–75th percentile, 4.1–28.6]; P <0.0001). Among those presenting at <34 weeks (n=167), the results were more striking (226.6 [25th–75th percentile, 50.4–547.3] versus 4.5 [25th–75th percentile, 2.0–13.5]; P <0.0001), and the risk was markedly elevated when the highest sFlt1/PlGF ratio tertile was compared with the lowest (odds ratio, 47.8; 95% confidence interval, 14.6–156.6). Among participants presenting at <34 weeks, the addition of sFlt1/PlGF ratio to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (area under the curve, 0.93 for hypertension, proteinuria, and sFlt1/PlGF versus 0.84 for hypertension and proteinuria alone; P =0.001). Delivery occurred within 2 weeks of presentation in 86.0% of women with an sFlt1/PlGF ratio ≥85 compared with 15.8% of women with an sFlt1/PlGF ratio <85 (hazard ratio, 15.2; 95% confidence interval, 8.0–28.7). Conclusions—: In women with suspected preeclampsia presenting at <34 weeks, circulating sFlt1/PlGF ratio predicts adverse outcomes occurring within 2 weeks. The accuracy of this test is substantially better than that of current approaches and may be useful in risk stratification and management. Additional studies are warranted to validate these findings.

1 January 2012 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SVStefan Verlohren
Stefan Verlohren
IHIgnacio Herraiz
Ignacio Herraiz
OLOlav Lapaire
Olav Lapaire
DSDietmar Schlembach
Dietmar Schlembach
MMManfred Moertl
Manfred Moertl
HSHolger Stepan
Holger Stepan

1 February 2010 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SVStefan Verlohren
Stefan Verlohren
AGAlberto Galindo
Alberto Galindo
DSDietmar Schlembach
Dietmar Schlembach
HZHarald Zeisler
Harald Zeisler
IHIgnacio Herraiz
Ignacio Herraiz
HSHolger Stepan
Holger Stepan

1 February 2014 in Hypertension
Verified
Journal Article
Closed access
PDF file
SVStefan Verlohren
Stefan Verlohren
IHIgnacio Herraiz
Ignacio Herraiz
OLOlav Lapaire
Olav Lapaire
DSDietmar Schlembach
Dietmar Schlembach
HZHarald Zeisler
Harald Zeisler
HSHolger Stepan
Holger Stepan
To establish gestational phase adapted cutoffs for the use of the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio as a diagnostic tool for preeclampsia in the clinical setting, a multicenter case–control study including a total of 1149 patients was performed. We report normal values of sFlt-1, PlGF, and the sFlt-1/PlGF ratio based on the analysis of a total of 877 patients with uneventful pregnancy outcome. A total of 234 patients with preeclampsia and a matched cohort consisting of 468 patients with normal pregnancy outcome were compared, and sFlt-1 and PlGF were measured on an automated platform. Separate cutoffs for the sFlt-1/PlGF ratio were determined for the early (20+0–33+6 weeks) and the late gestational phase (34+0 weeks–delivery). For each of the 2 gestational phases, 2 independent cutoffs framing an equivocal zone were determined: the first cutoff with focus on high sensitivity, and the second focusing on high specificity. Between 20+0 and 33+6 weeks, the cutoffs at ≤33 and ≥85 resulted in a sensitivity/specificity of 95%/94% and 88%/99.5%, respectively. An sFlt-1/PlGF ratio of ≤33 had the lowest likelihood of a negative test (0.05; 95% confidence interval, 0.02–0.13), whereas values ≥85 had the highest likelihood of a positive test (176; 95% confidence interval, 24.88–1245). After 34+0 weeks, the cutoffs at ≤33 and ≥110 yielded a sensitivity/specificity of 89.6%/73.1% and 58.2%/95.5%, respectively. The approach to use multiple cutoffs for the early and late gestational phase enhances the diagnostic accuracy of the sFlt-1/PlGF ratio as a diagnostic tool for preeclampsia.

3 March 2015 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
HSH. Stepan
H. Stepan
IHI. Herraiz
I. Herraiz
Dietmar SchlembachDietmar Schlembach
Dietmar Schlembach
SVS. Verlohren
S. Verlohren
SBShaun Brennecke
Shaun Brennecke
AGA. Galindo
A. Galindo